Sugi Predict

Sugi Predict / Compounds / SCHEMBL21332946

SCHEMBL21332946

SCHEMBL21332946

Cc1c(C(=O)Cn2cc(Br)ccc2=O)cnn1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR2 O95136 1/20 0.47
▸ PTGDR2 Q9Y5Y4 6/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PFKFB3 Q16875 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ MAPT P10636 4/20 0.39
▸ POLB P06746 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ BRD2 P25440 1/20 0.38
▸ BRD3 Q15059 1/20 0.38
▸ BRDT Q58F21 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21333289 0.93 S1PR2 (0.43) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL21333280 0.90 KDM4E (0.39) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL21332885 0.89 PTGDR2 (0.41) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL30866465 0.89 KMT2A (0.42) S1PR2PTGDR2SMN1; SMN2KMT2APOLB
SCHEMBL21333435 0.89 KMT2A (0.42) S1PR2PTGDR2SMN1; SMN2KMT2APOLB
SCHEMBL21332657 0.87 S1PR2 (0.41) S1PR2PTGDR2KDM4EKMT2APFKFB3
SCHEMBL21333532 0.87 KDM4E (0.44) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL21332978 0.87 S1PR2 (0.47) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL21333070 0.86 S1PR2 (0.46) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A
SCHEMBL21332979 0.86 KDM4E (0.43) S1PR2PTGDR2KDM4ESMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3762377-B1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF UNIV CORNELL (US) 2025-08-20 — — EP disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 — — US disclosed
EP-3762377-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF Cook, Timothy, H. (US) 2021-01-13 — — EP disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 — — US disclosed
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2020-12-31 — — US disclosed
WO-2019173790-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF HLA TIMOTHY (US) 2019-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407339-A1 PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF PTGER1, LOXL1, COL1A1 S1PR2 601/4885PTGDR2 103/4885KDM4E 2671/4885
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof PTGER1, LOXL1, COL1A1 S1PR2 601/4885PTGDR2 103/4885KDM4E 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.